New lupus drugs aim to tame the Body's attack

NCT ID NCT03656562

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study tested two experimental drugs, VAY736 and CFZ533, in people with active lupus to see if they are safe and can help control the disease. Over 100 participants were randomly assigned to receive either one of the drugs or a placebo for 28 weeks, followed by a period where everyone could receive the active treatment. The main goal was to see if the drugs could reduce lupus disease activity enough for patients to safely lower their steroid medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Ciudad Autonoma de Bs As, Buenos Aires, C1015ABO, Argentina
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Guangzhou, Guangdong, 510000, China
Novartis Investigative Site

Nanjing, Jiangsu, 210008, China
Novartis Investigative Site

Shanghai, 200127, China
Novartis Investigative Site

Prague, 128 00, Czechia
Novartis Investigative Site

Pessac, 33604, France
Novartis Investigative Site

Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
Novartis Investigative Site

Berlin, 10117, Germany
Novartis Investigative Site

Budapest, 1023, Hungary
Novartis Investigative Site

Debrecen, 4032, Hungary
Novartis Investigative Site

Ramat Gan, 5265601, Israel
Novartis Investigative Site

Nagoya, Aichi-ken, 457 8510, Japan
Novartis Investigative Site

Nagoya, Aichi-ken, 460-0001, Japan
Novartis Investigative Site

Chuo Ku, Tokyo, 104 8560, Japan
Novartis Investigative Site

Shinjuku Ku, Tokyo, 162 8655, Japan
Novartis Investigative Site

Shinjuku-ku, Tokyo, 160 8582, Japan
Novartis Investigative Site

Bydgoszcz, 85 168, Poland
Novartis Investigative Site

Poznan, 60-218, Poland
Novartis Investigative Site

Warsaw, 00-874, Poland
Novartis Investigative Site

Moscow, 115522, Russia
Novartis Investigative Site

Saint Petersburg, 194044, Russia
Novartis Investigative Site

Yekaterinburg, 620144, Russia
Novartis Investigative Site

Gwangju, 61469, South Korea
Novartis Investigative Site

Barcelona, Catalonia, 08035, Spain
Novartis Investigative Site

Barcelona, 08041, Spain
Novartis Investigative Site

Taichung, Taiwan ROC, 40201, Taiwan
Novartis Investigative Site

Taichung, 40447, Taiwan
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Bangkok, 10400, Thailand
Novartis Investigative Site

Bangkok, 10700, Thailand

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)